Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma, Large Cell Carcinoma), By Treatment (Chemotherapy, Immunotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Non-small Cell Lung Cancer Therapeutics Market Summary

Increased consumption of tobacco products, deterioration of air quality due to air pollution, and unhealthy lifestyles have also contributed to the increase in lung cancer. Furthermore, increased investments by major medical institutes for research and development of medicines and treatments related to NSCLC have resulted in the growth of this market.

The rising incidence of lung cancer, primarily driven by excessive smoking and tobacco use, has significantly expanded the market. Smoking causes around 90% of lung cancer cases due to exposure to carcinogenic chemicals. With lung cancer diagnoses in the U.S. projected to exceed 226,000 cases by 2025, the demand for effective prevention, diagnosis, and treatment is escalating. In addition, exposure to hazardous substances such as radon gas, air pollution, passive smoking, and unsafe water consumption contributes to the growing disease burden.

The World Health Organization (WHO) identifies tobacco as a major health threat, responsible for over 8 million deaths annually, with a disproportionate impact in low- and middle-income countries. WHO advocates for measures such as smoke-free laws, advertising bans, and tax hikes to reduce tobacco consumption and promote smoking cessation.

In response to this rising demand for therapies, market players are innovating treatment platforms, particaularly in immuno-oncology. Immune-modulating therapies and T-cell-based platforms are expanding clinical applications, improving therapeutic diversity, and addressing treatment-resistant cancers. These efforts also foster regulatory engagement, attract investment, and drive strategic collaborations. For example, in April 2024, ImmunityBio announced positive survival results from the QUILT 3.055 trial, where ANKTIVA (nogapendekin alfa inbakicept-pmln), in combination with checkpoint inhibitors, nearly doubled survival in 2nd- and 3rd-line NSCLC patients unresponsive to prior therapies. A June 2024 FDA meeting is scheduled to discuss registration, with the company also preparing for ANKTIVA's NMIBC launch.

Pipeline Analysis 

The evolving therapeutic landscape for non-small cell lung cancer (NSCLC) is being shaped by significant advances in clinical research and the expansion of immuno-oncology pipelines. The emergence of immune checkpoint inhibitors, monoclonal antibodies, and biomarker-driven therapies has accelerated the development of novel treatments aimed at improving patient outcomes. As leading pharmaceutical companies intensify efforts across both first-line and adjuvant/neoadjuvant settings, the NSCLC pipeline reflects a shift toward personalized, multi-modal approaches that address unmet clinical needs. This pipeline momentum is contributing directly to market growth by increasing product differentiation, extending treatment durations, and expanding eligible patient populations. It also supports competitive innovation and drives regulatory engagement, fueling commercial opportunities and investment interest across global markets.

In December 2024, Incyte reported positive results from its Phase 3 POD1UM-304 trial evaluating retifanlimab, a humanized monoclonal antibody targeting PD-1, in combination with platinum-based chemotherapy for previously untreated metastatic NSCLC. The trial demonstrated a median overall survival of 18.1 months versus 13.4 months for the control group, meeting its primary endpoint with statistically significant improvements. Secondary endpoints, including overall response rate and progression-free survival, also improved, supporting a 2025 sBLA filing in the U.S.

Other key players such as AstraZeneca, Merck, Amgen, and Bristol Myers Squibb are advancing robust portfolios focused on both early and advanced-stage NSCLC. Although challenges like tumor heterogeneity and immunotherapy resistance persist, the pipeline’s depth and diversity underscore a promising market trajectory driven by continuous innovation, improved efficacy profiles, and expanding therapeutic applications.

Market Concentration & Characteristics

The degree of innovation is significant in the market characterized by a growing level of research and development. For instance, according to the National Cancer Institute, a combination of BRAF-targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist), which targets a protein called MEK, has been approved as a treatment for patients with NSCLC with a specific mutation in the BRAF gene. B-Raf protein primarily sends signals in cells and plays a significant role in cell growth. Certain changes in the BRAF gene can increase the growth and spread of NSCLC cells.

Several players engage in mergers & acquisitions to strengthen their market positions. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve competency. For instance, in November 2024, Roche announced that it had finalized a merger deal to buy Poseida Therapeutics, Inc., a pioneering public clinical-stage biopharmaceutical company in donor-derived CAR-T cell therapies.

Regulations in the market set standards for safety, efficacy, and accessibility. They govern approval processes, manufacturing standards, labeling, and surveillance. For instance, the American Cancer Society's standardized training and credentialing program in Oncology Navigation (ACS LION) helps navigators deliver essential support to individuals and families experiencing cancer. The program fulfills all the training requirements for "Principal Illness Navigation" reimbursement by the Centers for Medicare & Medicaid Services (CMS) and aligns with Professional Oncology Navigation (PONT) standards. Compliance is vital for companies to introduce and sustain their products, and regulations protect patients by minimizing risks and ensuring accurate information.

Service providers are undertaking strategic initiatives to expand facilities to rural areas around the globe, trying to reduce the need for patients and their caregivers to travel to hospitals and giving them more time to go about their daily lives. For instance, in July 2024, The Global Capability Centre (GCC) of AstraZeneca, AstraZeneca India Private Limited (AZIPL), announced a 250-crore rupee (USD 30 million) investment to expand its Global Technology and Innovation Centre (GITC) in different parts of India, which includes nearly 1,300 positions focused on enhancing efficiency, driving innovation, and streamlining operations across the company around the globe.

The level of regional expansion of the industry is significant due to the growing need for advanced treatment in populated areas. For instance, in May 2024, Healthcare Global Enterprises Limited, a healthcare provider, expanded its cancer care centers to two different locations in Bengaluru, India. The new locations offer personalized treatment, high-precision diagnosis, and comprehensive care.

Type Insights 

The adenocarcinoma segment dominated the market in 2024 with a share of 43.39% in 2024 due to an increase in the population consuming tobacco and other products for smoking. Smoking addiction is one of the major reasons for patients diagnosed with adenocarcinoma. The segment is growing as the detection of adenocarcinoma is done at an early stage, which allows for better treatment. Furthermore, an increase in the targeted drugs used specifically to treat adenocarcinoma has further contributed to the market growth.

The squamous cell carcinoma (SCC) segment is anticipated to witness the fastest CAGR over the forecast period. This market growth is attributed to the rise in the patients exposed to UV radiation. SCC usually occurs in the neck and head region, including the nasal cavity, throat, lips, and tongue regions. Furthermore, the awareness campaigns about SCC run by medical institutions and governments have led to more patients seeking treatment for the condition. Therefore, these factors are responsible for the market growth of this segment.

Treatment Insights

The targeted therapy segment dominated the market in 2024 with a share of 50.66% in 2024. The factors responsible for the market growth are the benefits of this therapy, such as an increased number of targeted therapeutics and a low percentage of side effects during the treatment. Targeted therapies are specifically used to disrupt cancer cell growth signals. Targeted therapies can be customized according to the patient type, which helps in minimizing the side effects. Hence, these reasons are responsible for the upward market growth of this segment.

The immunotherapy segment is expected to grow at a significant CAGR over the forecast period due to introduction of new products in the immunotherapy segment and an increase in the preference for immunotherapy to treat cancer. Immunotherapy uses the immunity system to cure and control the cancer-causing cells in the patient’s body. Furthermore, increased investments by key market players to develop better products to optimize the treatment have also helped in the market growth of this segment.

Distribution Channel Insights

The hospital pharmacy segment dominated the market with a share of 66.89% in 2024. This market growth was attributed to the increase in the number of hospitalized patients suffering from NSCLC. Increase in the number of medicines and treatments available for treating NSCLC has further contributed to the market growth of the segment, as key market players are targeting to deploy more regulatory-approved medicines to treat these disorders. The above-mentioned reasons are responsible for the market growth of hospital pharmacy segment.

The drug store and retail pharmacy segment is anticipated to witness a significant CAGR over the forecast period, owing to the increased availability of regulatory-approved drugs for consumption by patients seeking to cure NSCLC. Increased prevalence of lung cancer has resulted in a high demand for medications and treatments. Therefore, drug stores and retail pharmacies provide convenient access to medications. Furthermore, increased awareness about cancer treatment has increased in number of patients seeking to consume medicines that help in the treatment of lung disorders. Therefore, these factors have resulted in the market growth of this segment.

Regional Insights 

North America Non-small Cell Lung Cancer (NSCLC) therapeutics industry dominated globally with a market share of 35.41% in 2024. This growth was attributed to the presence of developed healthcare facilities and increased awareness regarding cancer treatments. The market is also growing due to the presence of key market players who are targeting to deploy new and more effective medicines to treat NSCLC. A rise in the disposable income has increased the acceptance of costly treatments and drugs, which further helps in the market growth of this region.

U.S. Non-small Cell Lung Cancer Therapeutics Market Trends

The Non-small Cell Lung Cancer (NSCLC) therapeutics industry in the U.S. dominated themarket in the North America region in 2024 with the largest revenue share. This large share is attributed to the rise in the population with smoking addiction and air pollution. The presence of major medical institutes in the country helps in diagnosing the early stages of cancer. Major companies are investing heavily in the development of medicines and therapeutics, which is contributing to market growth. Furthermore, growing awareness related to cancer treatment has increased the number of patients seeking diagnosis and treatment for their disorders.

Europe Non-small cell lung cancer therapeutics market Trends

Europe Non-small Cell Lung Cancer therapeutics industry was identified as a lucrative regional industry due to the presence of major medical institutes and an increase in the population with smoking addiction. Furthermore, increased awareness about cancer treatment by the government and various NGOs has increased the number of patients seeking treatment for NSCLC. Therefore, these factors are responsible for the positive market growth in this region.

The UK non-small cell lung cancer therapeutics industry is expected to grow rapidly due to the increasing prevalence of cancer diseases and introduction of new drugs and therapies for the treatment of NSCLC. Rising awareness and early detection efforts have increased the diagnosis rates of various cancer disorders. Furthermore, an increase in the drugs approved by the regulatory bodies has also helped in the market growth of NSCLC therapeutics in this country.

Non-small Cell Lung Cancer (NSCLC) therapeutics market in Germany is driven by its advanced healthcare infrastructure, widespread access to diagnostic tools for molecular profiling, and early adoption of precision therapies. Reimbursement policies and hospital treatment protocols support the integration of targeted and immunotherapy regimens.

France Non-small Cell Lung Cancer (NSCLC) therapeutics industry is expanding due to high disease prevalence, supportive national health programs, and increasing utilization of biomarker-driven treatments. The centralized healthcare system facilitates equitable access to novel therapeutics.

Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Trends

The Non-small Cell Lung Cancer (NSCLC) therapeutics industry in Asia Pacific is witnessing rapid growth fueled by rising lung cancer incidence, government investment in oncology care, and growing regional partnerships to expand access to biologics and targeted drugs.

Japan Non-small Cell Lung Cancer (NSCLC) therapeutics industry is supported by aging demographics, focus on early cancer detection, and integration of personalized medicine in oncology protocols. Local pharmaceutical innovation and regulatory efficiency also contribute to market expansion.

Non-small Cell Lung Cancer (NSCLC) therapeutics industry in China is growing rapidly due to high smoking-related cancer burden, policy-driven acceleration of drug approvals, and increasing insurance coverage for targeted and immune-based therapies.

Latin America Non-small Cell Lung Cancer Therapeutics Market Trends

Latin America Non-small Cell Lung Cancer (NSCLC) therapeutics industry is experiencing steady growth driven by rising urbanization-related risk factors, gradual healthcare system modernization, and expanded public health focus on cancer control programs.

Brazil Non-small Cell Lung Cancer (NSCLC) therapeutics industry benefits from increasing diagnosis rates, improving oncology treatment infrastructure, and governmental prioritization of access to essential therapies through public health channels.

Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Trends

The Middle East & Africa Non-small Cell Lung Cancer (NSCLC) therapeutics industry is emerging due to increasing incidence of respiratory cancers, growing investment in healthcare systems, and policy support for expanding cancer care capabilities.

Saudi Arabia Non-small Cell Lung Cancer (NSCLC) therapeutics industry is expanding due to the rising burden of lung cancer, strategic healthcare reforms, and initiatives aimed at boosting access to advanced therapeutic technologies in oncology.

Key Non-small Cell Lung Cancer Therapeutics Company Insights

The Non-small Cell Lung Cancer therapeutics industry is undergoing dynamic shifts as next-generation therapies reshape the treatment paradigm. In 2024, the competitive landscape has become increasingly multifaceted, with a growing number of targeted therapies, immunotherapies, and combination regimens achieving regulatory clearance and expanding globally. These advancements are enhancing therapeutic precision and survival outcomes for patients across disease stages.

Market-leading pharmaceutical companies are advancing differentiated portfolios through biomarker-driven drug development, tumor-agnostic approvals, and combination therapy protocols. Strategic collaborations-spanning research institutions, biotechnology firms, and diagnostics companies-are reinforcing pipeline strength and accelerating clinical translation. These shifts are fostering a competitive, innovation-intensive environment that continues to expand patient access, reduce mortality, and redefine standards of care in lung oncology.

Recent Developments

• In April 2025, Akeso Inc. received approval from China's National Medical Products Administration (NMPA) for Ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, as a monotherapy for the first-line treatment of patients with advanced, PD-L1-positive (tumor proportion score ≥1%) non-small cell lung cancer (NSCLC) without EGFR or ALK mutations.

• In August 2024, AstraZeneca’s Imfinzi, a type of immunotherapy used to treat various cancers in combination with chemotherapy, was approved by the U.S. FDA for the treatment of adult patients with resectable early-stage NSCLC and no known Epidermal Growth Factor Receptor (EGFR) mutations or Anaplastic Lymphoma Kinase (ALK) rearrangements.

• In October  2024, Novocure announced that the U.S. Food and Drug Administration (FDA) approved Optune Lua for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after a platinum-based chemotherapy regimen. Optune Lua is a wearable device that delivers Tumor Treating Fields (TTFields), a novel therapy that uses alternating electric fields to disrupt cancer cell division, leading to cell death.

• In May 2024, Pfizer Inc. announced longer-term follow-up results from the phase 3 CROWN trial evaluating LORBRENA versus XALKORI for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After 5 years of median follow-up, there was an 81% reduction in the disease progression rate.

• In March 2023, F. Hoffmann-La Roche Ltd. announced the approval of VENTANA PD-L1 (SP263) Assay as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients. The company believed that with this launch, more patients would have access to an additional immunotherapy option.

Non-Small Cell Lung Cancer Therapeutics Market Report Scope

Global Non-Small Cell Lung Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global non-small cell lung cancer therapeutics market report based on type, treatment, distribution channel, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Squamous Cell Carcinoma

  • Large Cell Carcinoma

  • Adenocarcinoma

  • Others

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

  • Targeted Therapy

  • Immunotherapy

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Drug Store and Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait